Tofacitinib is a Janus kinase (JAK) inhibitor categorized as an immunosuppressant, primarily indicated for the treatment of moderate-to-severe rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis,… Read more











![Chemical structure of N1-methyl-N1-((3R,4R)-4-methyl-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-3-yl)malonamide](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F2504210-30-2-N1-methyl-N1-3R4R-4-methyl-1-7H-pyrrolo23-dpyrimidin-4-ylpiperidin-3-ylmalonamide.png&w=3840&q=75)


![Chemical structure of N2,N4-bis((3R,4R)-1-benzyl-4-methylpiperidin-3-yl)-N2,N4-dimethyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F2459302-78-2-N2N4-bis3R4R-1-benzyl-4-methylpiperidin-3-yl-N2N4-dimethyl-7H-pyrrolo23-dpyrimidine-24-diamine.png&w=3840&q=75)

































Tofacitinib is a Janus kinase (JAK) inhibitor categorized as an immunosuppressant, primarily indicated for the treatment of moderate-to-severe rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis. In pharmaceutical analysis, Tofacitinib and its related compounds, including impurities, metabolites, and stable isotope labelled standards, are essential for rigorous quality control and regulatory compliance. These reference standards enable accurate impurity profiling, allowing laboratories to identify and quantify process-related compounds, degradation products, and synthetic intermediates. By utilizing characterized reference materials, analysts can perform robust method validation, ensuring the sensitivity and reliability of analytical techniques such as high-performance liquid chromatography and mass spectrometry. The inclusion of stable isotope labelled compounds provides critical internal standards for precise quantitative analysis, supporting the development of stable, reproducible pharmaceutical processes and ensuring therapeutic safety in accordance with global guidelines for drug development.